Simcere has consistently maintained a high level of investment in innovation and R&D. Over the past five years, the company has invested nearly CNY 9 billion in research and development.
With innovation centers in Nanjing, Shanghai, Beijing, and Boston, Simcere has built a comprehensive R&D system that integrates drug discovery, preclinical development, clinical trials, and drug registration. The company currently has over 60 projects in its new drug development pipeline.
Additionally, Simcere has assembled an R&D team of over 1,000 professionals, more than 70% of whom hold master's or doctoral degrees, and over 10% have international experience.